His-bundle pacing, diet soft drinks, beta-blockers, chest-pain evaluation, and the LDL hypothesis are discussed in this week's podcast.

Longevity is seductive, but it comes with consequences. Drs Piña and Forman discuss a new AHA scientific statement on physical and cognitive function considerations in the older patient with CVD.

Drs Widmer, Joyce, and Holmes discuss how results of recent trials influence their treatment of coronary artery disease and their thoughts about the future.

High-sensitivity troponin, statin eligibility, FDA letter to Abbott, azithromycin risks, trans-fat ban, and trust in medical science are discussed by Dr John Mandrola in this week's podcast.

Cardiac arrest care setting, ICDs in patients with nonischemic cardiomyopathy, BP control, readmissions in the elderly with HF, and cardiologists' pay are discussed in this week's podcast.

Dr Wharton narrates a case where all is not quite as it seems: A woman is experiencing heart palpitations. Years ago, her cardiologist told her she had severe mitral regurgitation.

Dr De Ferrari provides details on a substudy of the ARISTOTLE trial that examined digoxin blood levels and mortality in patients with and without heart failure.

Cost effects of risk-factor management in AF, apixaban costs vs warfarin, bioresorbable-scaffold woes, exercise as heart-failure therapy, and surgical left atrial appendage closure are discussed.

Dr Makkar provides more insights from the SAVORY and RESOLVE registries on the phenomenon of bioprosthetic valve leaflet thrombosis seen on 4D CT.

High-sensitivity troponin testing, dabigatran during AF ablation, valve-in-valve TAVR, Impella, and the ARNI valsartan/sacubitril's effect on HbA1c are discussed in this week's podcast.